Matthew S Shotwell, Ross Nesbitt, Phillip N Madonia, Edward R Gould, Michael J Connor, Charbel Salem, Olufemi A Aduroja, Milen Amde, Joseph J Groszek, Peilin Wei, Maria E Taylor, Ashita J Tolwani, William H Fissell
BACKGROUND AND OBJECTIVES: Infection is the most common cause of death in severe AKI, but many patients receiving continuous RRT do not reach target antibiotic concentrations in plasma. Extended infusion of β-lactams is associated with improved target attainment in critically ill patients; thus, we hypothesized that extended infusion piperacillin-tazobactam would improve piperacillin target attainment compared with short infusion in patients receiving continuous RRT. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted an institutional review board-approved observational cohort study of piperacillin-tazobactam pharmacokinetics and pharmacodynamics in critically ill patients receiving continuous venovenous hemodialysis and hemodiafiltration at three tertiary care hospitals between 2007 and 2015...
August 8, 2016: Clinical Journal of the American Society of Nephrology: CJASN